1. Big Pharma Is Urged to Report on Links Between Pricing and Pay

    Big Pharma Is Urged to Report on Links Between Pricing and Pay

    Pharmaceutical companies should be required to regularly report whether there’s a link between drug-pricing strategies and executive-compensation plans, according to a shareholder group. The Interfaith Center on Corporate Responsibility , a coalition of institutional investors with more than $400 billion of assets, said in a statement Wednesday that it submitted proposals for inclusion at the 2018 annual meetings of Abbvie Inc., Amgen Inc., Biogen Inc., Bristol Myers Squibb Co. and Eli Lilly & Co. “An executive compensation incentive program reliant on revenue growth solely from drug price increases is a risky and unsustainable strategy,” the group said in the statement ...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. An executive compensation incentive program reliant on revenue growth solely from drug price increases is a risky and unsustainable strategy.
  3. Topics Mentioned

  4. Authors